Key Takeaways:
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) priced an offering of $600 million in convertible senior notes due 2032, securing capital with a 0.00% interest rate at a significant premium to its recent stock price. The deal comes as the company’s shares trade near a 52-week high.
The initial conversion price is set at approximately $138.94 per share, a 30% premium over the $106.88 closing price of Mirum’s common stock on May 12, according to a company statement. The notes will not bear regular interest and are set to mature on June 1, 2032, unless converted, redeemed, or repurchased earlier.
Mirum estimates net proceeds of approximately $583.8 million, or up to $671.6 million if initial purchasers fully exercise their option to buy an additional $90 million in notes. The company plans to use about $475 million of the proceeds and 3.2 million of its shares to exchange a portion of its 4.00% convertible notes due 2029, with the remainder allocated for general corporate purposes and potential acquisitions.
The offering follows a strong period for Mirum’s stock, which has returned 136% over the past year. The financing also coincides with positive sentiment from Wall Street, with firms including Baird and Raymond James recently raising their price targets on the stock. Baird adjusted its target to $129, citing strong performance and the success of the company’s liver disease drug, Livmarli.
This debt refinancing and capital raise strengthens Mirum’s balance sheet as it continues to expand its portfolio of treatments for rare diseases. The conversion feature of the notes could lead to future shareholder dilution, but the favorable 0.00% interest rate provides low-cost financing. Investors will now watch the integration of this new capital and any potential acquisition activity. The transaction is expected to settle on May 15, 2026.
This article is for informational purposes only and does not constitute investment advice.
